Accelerating clinical trials in the EU (ACT EU): transforming the EU clinical trials landscape

IF 122.7 1区医学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Nature Reviews. Drug Discovery Pub Date : 2024-05-23 DOI:10.1038/d41573-024-00085-5

Giacomo Capone, Björn Eriksson, Monique Al, Stan van Belkum, Karl Broich, Maria Lamas, Marianne Lunzer, Lorraine Nolan, Catriona Ester, Juan Garcia Burgos, Laura Pioppo, Ana Zanoletty, Peter Arlett

{"title":"Accelerating clinical trials in the EU (ACT EU): transforming the EU clinical trials landscape","authors":"Giacomo Capone, \n Björn Eriksson, \n Monique Al, \n Stan van Belkum, \n Karl Broich, \n Maria Lamas, \n Marianne Lunzer, \n Lorraine Nolan, \n Catriona Ester, \n Juan Garcia Burgos, \n Laura Pioppo, \n Ana Zanoletty, \n Peter Arlett","doi":"10.1038/d41573-024-00085-5","DOIUrl":null,"url":null,"abstract":"Accelerating Clinical Trials in the EU (ACT EU) is an initiative developed by the European Commission, Heads of Medicines Agencies and the European Medicines Agency to transform the clinical trials landscape in the European Union. It aims to foster regulatory, technological and process innovation to support better, faster and optimized clinical trials. Accelerating Clinical Trials in the EU (ACT EU) is an initiative developed by the European Commission, Heads of Medicines Agencies and the European Medicines Agency to transform the clinical trials landscape in the European Union. It aims to foster regulatory, technological and process innovation to support better, faster and optimized clinical trials.","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"23 11","pages":"797-798"},"PeriodicalIF":122.7000,"publicationDate":"2024-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews. Drug Discovery","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/d41573-024-00085-5","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Accelerating Clinical Trials in the EU (ACT EU) is an initiative developed by the European Commission, Heads of Medicines Agencies and the European Medicines Agency to transform the clinical trials landscape in the European Union. It aims to foster regulatory, technological and process innovation to support better, faster and optimized clinical trials. Accelerating Clinical Trials in the EU (ACT EU) is an initiative developed by the European Commission, Heads of Medicines Agencies and the European Medicines Agency to transform the clinical trials landscape in the European Union. It aims to foster regulatory, technological and process innovation to support better, faster and optimized clinical trials.

查看原文本刊更多论文

加速欧盟临床试验（ACT EU）：改变欧盟临床试验格局。

欧盟加速临床试验（ACT EU）是欧盟委员会、药品机构负责人和欧洲药品管理局为改变欧盟临床试验格局而制定的一项倡议。它旨在促进监管、技术和流程创新，以支持更好、更快和更优化的临床试验。欧盟加速临床试验（ACT EU）是由欧盟委员会、各药品管理局负责人和欧洲药品管理局共同制定的一项倡议，旨在改变欧盟的临床试验状况。它旨在促进监管、技术和流程创新，以支持更好、更快和更优化的临床试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews. Drug Discovery 医学-生物工程与应用微生物

CiteScore

137.40

自引率

0.30%

发文量

227

期刊介绍： Nature Reviews Drug Discovery is a monthly journal aimed at everyone working in the drug discovery and development arena. Each issue includes: Highest-quality reviews and perspectives covering a broad scope. News stories investigating the hottest topics in drug discovery. Timely summaries of key primary research papers. Concise updates on the latest advances in areas such as new drug approvals, patent law, and emerging industry trends and strategies.